Gilead: New Remdesivir Data Set Up A Potential Short Trade
On Thursday, April 16, STAT put up an article by Adam Feuerstein and Matthew Herper
- These details weren't officially from GILD via press release ..
-- I'm inclined to trust the source here even if that video isn't available, but I am not inclined to believe the numbers offer proof of efficacy for remdesivir.
-- Lastly, anyone shorting GILD is exposed to readouts from other remdesivir studies, not just the US severe COVID-19 study.
-- I think that data from the Chinese mild/moderate study won't show anything as too few patients
-- What is going on with the Chinese trials?
Summary
An "early peek" at data from GILD's US/international study of remdesivir in COVID-19 has the market excited, GILD is trading up.I don't think the numbers are exciting.
-We need to wait for results from these trials.Chinese studies of remdesivir have stalled and the mild/moderate COVID-19 study of remdesivir may not have enrolled many patients at all.